Status:
COMPLETED
Effect of Patient Demographics, Comorbidities, and Medications on Severity of NASH Fibrosis
Lead Sponsor:
Methodist Health System
Conditions:
Non-Alcoholic Fatty Liver Disease
Non Alcoholic Steatohepatitis
Eligibility:
All Genders
18+ years
Brief Summary
Few studies have evaluated an extensive list of possible risk factors for NAFLD for their association with presence and severity of histologic features. We wish to conduct a retrospective study on the...
Detailed Description
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in Western countries, and is projected to become one of the foremost indications for liver transplantation (...
Eligibility Criteria
Inclusion
- Patients identified to have biopsy-proven NASH within April 2013 - June 2020
- Minimum age 18, no upper limit of age
- Patients with complete records
Exclusion
- Age \<18 years
- Incomplete records
- Diseases other than NASH
Key Trial Info
Start Date :
May 24 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 7 2021
Estimated Enrollment :
263 Patients enrolled
Trial Details
Trial ID
NCT05357352
Start Date
May 24 2019
End Date
April 7 2021
Last Update
May 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Methodist Dallas Medical Center
Dallas, Texas, United States, 75203